Cold chain News and Research

RSS

ATCC announces new award from BARDA to provide centralized storage and bioprocessing services for Project NextGen

ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support the development of next-generation medical countermeasures (MCMs) to protect Americans from public health security threats such as coronaviruses.

From ATCC 5 Jan 2024

New dry powder aerosol COVID-19 vaccine shows promise against multiple virus strains

Study introduces a novel dry powder aerosol COVID-19 vaccine, showing its effectiveness in inducing strong immune responses and offering protection against various SARS-CoV-2 strains, including Omicron.

15 Dec 2023

Haier Biomedical recognized as the Most Innovative Sustainable Digital Healthcare Company 2023

Haier Biomedical is thrilled to be named as Global Health and Pharma's Most Innovative Sustainable Digital Healthcare Company for 2023.

From Haier Biomedical 11 Oct 2023

The safety and efficacy of the nano-based COVID-19 vaccine

A recent study evaluated the safety and efficacy of the GBP510 vaccine against SARS-CoV-2 infection.

12 Sep 2023

NIH awards $18 million to develop novel chikungunya vaccine

The Access to Advanced Health Institute (AAHI) announced today that it has received an $18 million award from the National Institutes of Health (NIH) to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus.

3 Aug 2023

Albumedix and Valneva expand collaboration to include newly approved inactivated COVID-19 vaccine

Albumedix Ltd., a recognized global leader in Recombinant Human Albumin (rHA), specializing in the enablement of advanced therapies and biopharmaceuticals, today announces the expansion of its existing collaboration with Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need.

From Albumedix Ltd. 29 Jun 2023

Print your own vaccine: automatic printing of microneedle patch COVID-19 mRNA vaccines

Researchers reported on the automatic printing of microneedle patch SARS-CoV-2 mRNA vaccines.

26 Apr 2023

Hemex Health awarded $3 million grant to advance commercialization of Gazelle Hb Variant Test for the U.S. market

Hemex Health, a medical diagnostic device company focused on expanding healthcare access to underrepresented patient populations, announced it has been awarded a 3-year, $3 million grant from the National Heart, Lung, and Blood Institute.

29 Mar 2023

PBD Biotech’s new lyophilized PCR reaction bead offers easy ambient shipping, extends global reach of active TB test

Tuberculosis testing and treatment needs to happen close to the point of infection. PBD Biotech has developed a lyophilized PCR reaction bead for its Actiphage® blood test for active TB.

16 Mar 2023

AAHI awarded a $9.9 million project to develop prototype intranasal bivalent influenza RNA vaccine candidate

The Access to Advanced Health Institute announced today that it has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium Other Transaction Authority to develop a prototype intranasal bivalent influenza RNA vaccine candidate based on AAHI's self-amplifying RNA (saRNA) platform that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.

6 Feb 2023

Promoting the One Health approach could greatly improve human-animal health and environmental integrity

Researchers pursued contemporary evidence of how One Health approaches could improve health security at a global scale against unprecedented health hazards, such as the one posed by the coronavirus disease 2019 (COVID-19) pandemic.

24 Jan 2023

Vaccine MVA-BN shows consistent, robust immunogenicity and safety results

A phase III clinical trial showed consistent immunogenicity for a freeze-dried formulation of Bavarian Nordic's Modified Vaccinia Ankara.

5 Dec 2022

Progress and challenges in the development of mRNA vaccines against respiratory syncytial virus

New research discussed the structure and life cycle of respiratory syncytial virus (RSV), the current research on the treatment and prevention of RSV infections, and the advancements in RSV mRNA vaccine technology after the surge in vaccine research during the COVID-19 pandemic.

1 Nov 2022

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

A new study evaluated the neutralizing antibody titers against the SARS-CoV-2 Omicron variant and its sub-lineages after two and three doses of the Novavax protein nanoparticle vaccine NVX-CoV2373.

31 Oct 2022

Vaccine hesitancy not the main barrier to immunization in low-income countries

Low vaccination rates in poorer countries have little to do with so-called “vaccine hesitancy” according to a study that examined access to COVID-19 tools across 14 low-income countries.

5 Oct 2022

3 shots in 1: How microparticles could be used to deliver self-boosting vaccines

In this interview, we speak to Morteza Sarmadi from MIT about his labs latest research that developed microparticles able to deliver self-boosting vaccines.

30 Aug 2022

Azenta announces agreement to acquire B Medical Systems

Azenta, Inc. announced it has entered into a definitive agreement to acquire B Medical Systems S.á r.l and its subsidiaries (“B Medical”).

From B Medical Systems S.à r.l 16 Aug 2022

SARS-CoV-2 receptor-binding domain-based protein subunit vaccine shows promise against multiple SARS-CoV-2 variants

Researchers described a novel protein subunit vaccine comprising the receptor-binding domain (RBD) of ancestral SARS-CoV-2 spike (S) protein, dimerized with an immunoglobulin (Ig)G1-fraction, crystallizable (Fc) domain.

11 Aug 2022

Three doses of Novavax vaccine effective against Omicron subvariants

Researchers report that Novavax COVID-19 vaccine triggers robust neutralization against SARS-CoV-2 Omicron subvariants.

26 Jul 2022

A different approach to build a more durable, broadly effective COVID-19 vaccine

Researchers at University of California San Diego School of Medicine, with colleagues elsewhere, describe a different way to build a COVID-19 vaccine, one that would, in theory, remain effective against new and emerging variants and could be taken as a pill, by inhalation or other delivery methods.

21 Jul 2022